Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spondyloarthritis (SpA) according to the new ASAS criteria for axial SpA~* BASDAI \> 40 mm despite NSAIDs~* Clinical indication for treatment with TNF-alpha inhibitor~* Age \> 18 years old and \< 85 years old~* Sufficient contraception for women~* Capable of giving informed consent~* Capable of complying with the examination program of the protocol~Exclusion Criteria:~* Pregnancy wish, pregnancy or breast-feeding~* DMARDs within 4 weeks prior to inclusion~* Oral, intra-articular or intramuscular glucocorticoid within 4 weeks prior to inclusion~* The use of other study drugs within 4 weeks prior to inclusion or less than 5 half-lives of the study drug before inclusion if this is more than 4 weeks~* The use of suspected disease-modifying or immunosuppressive drugs within 4 weeks prior to inclusion~* DMARDs are allowed during the study, but the dose cannot be changed from 4 weeks prior to inclusion through week~* Contraindications for TNF-α inhibitor treatment~* Contraindications for MRI~* Known recent drug or alcohol abuse~* Failure to provide written consent~* Incapable of complying with the examination program for physical or mental reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Adalimumab (Type: ACTIVE_COMPARATOR): TNF-alpha inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).